[Phase II study of 5-FU tablet in bladder tumor].
A cooperative-phase II study of 5-FU tablet at a dose of 200 to 300 mg/day (b.i.d. or t.i.d) on 27 patients with bladder cancer was performed at Yokohama City University and other affiliated hospitals. The therapeutic responses were evaluated by Koyama-Saito's criteria in 24 out of 27 patients, and 3 PR, 2 MR, 16 NC and 3 PD were obtained. The overall response rate was 12.5% (3/24). All of the responders received 5-FU tablets at a daily dose of 300 mg. Side effects were found in 2 out of 26 patients (7.7%). These were slight gastrointestinal symptoms. These results suggest that 5-FU tablet is a useful drug for bladder cancer.
Nagamoto
A
A
Dept. of Urology, Yokohama City University, School of Medicine.
Kubota
Y
Y
Shuin
T
T
Kondo
I
I
Moriyama
M
M
Satomi
Y
Y
Fukushima
S
S
Fukuoka
H
H
Ishizuka
E
E
Furuhata
A
A
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000855:Anorexia / Q000139:chemically induced; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D012074:Remission Induction; D013607:Tablets; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D013607:Tablets; D005472:Fluorouracil